Sarasota, FL — (PRESS RELEASE JET) — 09/13/2017 — Global Cardiac Marker Testing Market: Overview

When the heart is injured or stressed, it releases certain substances into the blood, which function as cardiac markers. The cardiac markers are usually enzymes, proteins, and hormones. Thus, quantification of these biomarkers can aid in diagnosing numerous heart disorders, including cardiac ischemia, acute coronary syndrome, and conditions linked to hindered blood supply to the heart. Physicians usually carry out multiple cardiac marker tests for hours to observe the blood level increase and to recognize the seriousness of a heart attack.

Request Free Sample Report @

Global Cardiac Marker Testing Market: Growth Factors

The major factors boosting the growth of global cardiac marker testing include rising expenditure by different institutes to encourage clinical and research studies in biomarker testing, increasing incidence of cardiovascular disorders, and increasing elderly population. However, issues related to storage and collection of samples, compensation, and strict regulatory recommendation are few factors that can hamper the growth of the global market. In addition, estimation of cardiac marker levels in the labs requires considerable time; thus, it cannot be used in the determination of myocardial infarction during the acute phase further restraining its use.

Global Cardiac Marker Testing Market: Segmentation

The global market for cardiac marker testing can be segmented based on disease, type of testing, product, type, and region. The disease segment of the market is divided into congestive heart failure and myocardial infarction. The type of testing segment of the market is diversified into point-of-care testing and laboratory testing. The product segment of the cardiac marker testing market is classified into immunofluorescence, immunochromatography, instruments, reagents and kits, chemiluminescence, and enzyme-linked immunosorbent assay. The type segment of the market is divided into C-reactive protein, troponin I and T, brain natriuretic peptide or NT-proBNP, CK-MB, other biomarkers, and myoglobin. The other biomarkers segment of the market is classified into H-FABP, homocysteine, myeloperoxidase, galectin-3, and ischemia-modified albumin. Regionally, the cardiac marker testing market is diversified into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Request Report TOC (Table of Contents) @

Global Cardiac Marker Testing Market: Regional Analysis

North America is anticipated to dominate the global market of cardiac markers testing. The various factors contributing to the growth of the market in this region include rising aging population, increasing inclination toward point-of-care testing, and elevated frequency of cardiovascular disorders. Asia-Pacific region is also expected to grow in the global market in the near future owing to the huge population, growing incidence of chronic heart diseases, and various measures taken to increase alertness about the diagnosis of cardiac diseases at an early stage.

Global Cardiac Marker Testing Market: Competitive Players

The key players in the global cardiac marker testing market include Siemens AG, Abbott Laboratories, Danaher Corporation, bioMérieux SA, Alere, Inc., Roche Diagnostics Ltd., Ortho Clinical Diagnostics, LSI Medience Corporation, and Randox laboratories Ltd. The other major players in the global market are Guangzhou Wondfo Biotech Co., Ltd., Bio-Rad Laboratories, Inc., Helomics Corporation, Becton, Dickinson and Company, Avantra Biosciences, and Enzo Biochem.

Browse detail report @

Global Cardiac Marker Testing Market: Regional Segment Analysis

North America
Asia Pacific
Latin America
Middle East & Africa

Powered by WPeMatico